News #MSParis2017 – Researchers Suggest Best Time to Stop Tysabri During Pregnancy #MSParis2017 – Researchers Suggest Best Time to Stop Tysabri During Pregnancy by Patricia Silva, PhD | October 27, 2017 Share this article: Share article via email Copy article link Babies born to women who are treated with Tysabri (natalizumab) during pregnancy are more likely to develop abnormal blood cell counts if the treatment continues beyond week 30 of pregnancy. Since more relapses occurred in women who quit the treatment before this time, researchers from the Ludwig Maximilian University of Munich in Germany concluded that 30 weeks was the optimal time interval to stop the treatment in pregnant women. The data was shown at a presentation at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France, a gathering of more than 9,000 researchers at one of the largest MS-focused meetings in the world. The risk of a drop in blood cell counts in babies born to mothers on Biogenās Tysabri is a known effect, but it rarely has been studied in relationship to relapses among mothers who quit the treatment during pregnancy. The study, āLong-term exposure to natalizumab during pregnancy ā a prospective case series from the German Multiple Sclerosis and Pregnancy Registry,ā turned to the German Multiple Sclerosis and Pregnancy Registry to determine if there was an optimal time to stop treatment with the drug. The team identified 40 women treated with Tysabri, enrolled in the registry. Among 32 babies in which blood cell counts were available upon birth, 15 had abnormally low cell counts. One-third was in the group of mothers who stopped treatment before week 24, and 39 percent were in the group who quit Tysabri before week 30. Babies had either anemia ā a lack of red blood cells ā or a lack of platelets. Only one newborn received treatment for the condition. Meanwhile, four women experienced relapses during pregnancy, of which three were in the group who quit Tysabri treatment before week 30. Eight more women had relapses after delivering their babies, of which three were in the group who quit before week 24, and five in the group who quit before week 30. Based on these data, researchers suggest that week 30 might be a good time to stop Tysabri treatment in pregnant women, for both the mother and the baby. However, in women with aggressive MS and higher disability, it may be necessary to continue the therapy beyond this time to reduce the risk for relapses. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags #MSParis2017, Biogen, Natalizumab, pregnancy, relapse, risk, Tysabri
April 24, 2024 News by Lindsey Shapiro, PhD Autoantibodies seen in blood years before MS diagnosis: Study
April 23, 2024 News by Mary Chapman Itās year 10 for MSAAās upcoming Improving Lives Benefit for MS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year